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Glutamic acid decarboxylase antibodies (GADAs) are one of the markers of islet cell autoimmunity and are sometimes present
before the onset of type 1 diabetes (T1D). GADA can be present in Graves’ patients without diabetes; however, the outcome of
GADA-positive Graves’ patients is not fully understood, and the predictive value of GADA for the development of T1D in Graves’
patients remains to be clariﬁed. We investigated the prevalence of GADA in 158 patients with Graves’ disease and detected GADA
in 10 patients. They were followed up to discover whether or not T1D developed. In the course of eight years, 2 patients with high
titers of GADA developed T1D, both had long-standing antithyroid drug-resistant Graves’ disease. Thus, Graves’ disease with high
GADA titer seems to be at high risk for T1D.
1.Introduction
Autoimmune type 1 diabetes (type 1A diabetes) is an organ-
speciﬁc autoimmune endocrine disease, which is caused by
immune destruction of pancreatic β cells [1]. Antibodies to
islet-related antigens including glutamic acid decarboxylase
antibodies (GADAs) and insulinoma-associated antigen 2
(IA-2) antibodies are markers for autoimmunity to islet cells
[2, 3]. When these antibodies are positive, the patient’s dia-
betes is usually considered to be type 1 even if they are not
insulin dependent [4–6]. Antibodies to islet-related antigens
are present before the onset of type 1 diabetes (T1D) [7],and
their predictive value for the development of T1D has been
repeatedly investigated in close relatives of T1D patients and
the general population [7–12].
Graves’ disease, which is also an organ-speciﬁc autoim-
mune endocrine disease, is frequently associated with T1D
[13]. In these patients, titers of GADA tend to be high [14],
which may indicate powerful ability of producing autoim-
mune process to islet antigens. On the other hand, GADA
is sometimes positive in Graves’ patients without diabetes
[15–17]. In these patients, GADA may exist independently
from β-cell destruction. However, the fate of Graves’ patients
who are positive for GADA is obscure, and the predictive
value of GADA for the development of T1D in Graves’
patients remains to be clariﬁed. We examined GADA in
patients with Graves’ disease and followed up patients who
were positive for GADA for 8 years.
2.Patientsand Methods
GADA was measured by a highly sensitive ligand-binding
assay in 158 patients with Graves’ disease (50 untreated, 108
treated) who had not been diagnosed to have diabetes. The
patients were randomly collected by one physician at Ito2 Journal of Thyroid Research
Thyroid Clinic. Most patients other than new patients
were under the treatment with antithyroid drugs. In the
patients who were positive for GADA by ligand-binding
assay (positive when detected), GADA was again measured
by radioimmunoassay (Cosmic Corporation, standard value
was <1.5U/ml), and antibodies to Islet Cell Antibodies
(ICAs) 512/IA-2 were measured by a ligand-binding assay
(positive when detected). Details of the ligand-binding
assay for GADA and antibodies to ICA512/IA-2 have
been described elsewhere [18, 19]. Glucose intolerance was
assessed by either oral glucose tolerance test or HbA1c (ref-
erence range: 4.3–5.8%) within a half year after the detection
of GADA. Diabetes was diagnosed by criteria of American
Diabetes Association. In the cases in which only HbA1c
was measured for the detection of glucose intolerance, less
than 5.8% was considered to be normal glucose tolerance.
Patients positive for GADA by ligand-binding assay were
followed up whether or not type 1 diabetes developed. In
seven patients whose GADA titers by ligand-binding assay
were relatively high and GADA by RIA were positive, HbA1c
and occasional plasma glucose were measured at least every
two years for eight years. GADA was occasionally measured
by radioimmunoassay. In other three patients who were
negative for GADA by RIA, physicians inquired whether or
not diabetes developed at every visiting to the outpatient
clinic. One patient was dropped out three years after the
initial workup. The patients who were negative for GADA at
the start of the study were not followed up.
3.Results
Ten patients out of 158 (6.3%) were positive for GADA
by the ligand-binding assay. Eight of these patients were
treated with antithyroid drugs (ATDs) and 2 were untreated
(treatment naive). The overall prevalence of positivity for
GADA among treated and untreated patients was 7.4% and
4.0%,respectively (Table 1). GADAwas again investigated by
standard radioimmunoassay (RIA) in 9 of the 10 patients,
and6were positive (Table 2).In4patients, titersbyRIAwere
over 20U/ml. ICA512/IA-2 antibodies were weakly positive
in 2 patients. An oral glucose tolerance test was performed
in 5 of the 10 GADA-positive patients. Of these, one patient
showed a diabetic pattern and another had impaired glucose
tolerance (this patient dropped out from study 3 years after
the initial workup). BMI of these patients was 19.9 and 21.0,
respectively. The other 3 patients had normal GTT. HbA1c
levels of the other 5 patients were within the normal range.
During the 8-year followup period, T1D developed with
marked hyperglycemia and ketosis in two patients whose
Graves’ disease was long standing and uncontrollable by
antithyroid drug. One of them showed diabetic pattern in
GTT at the initial work up, but HbA1c was within a normal
range (Section 3.1 and Table 2).
3.1. Case Reports. Patient 1 was a 44-year-old man (at the
diagnosis of T1D), in whom Graves’ disease developed at
age 21. He took an antithyroid drug (ATD), but 10–20mg
of methimazole was needed to maintain euthyroid. At age
Table 1:Prevalence ofGAD antibodies in Graves’patients who had
not been diagnosed with diabetes at the study start.
Patient number GADA(+) (%)
Graves’ disease 158 10 6.3
untreated 50 2 4.0
treated 108 8 7.4
Diﬀerence of prevalence is not statisticallysigniﬁcant.
42, GADA was detected. His oral glucose tolerance test
the next year showed a diabetic pattern (FPG 7.8mmol/L
(141mg/dL), 2 hours 14.3mmol/L (257mg/dL)). HbA1c
was 5.7%. His insulin response to oral glucose was very
low (insulinogenic index, 0.08). GADA by RIA was as
high as 6090U/ml. Calorie restriction was recommended,
but symptoms of severe hyperglycemia including thirst and
polyuria developed the following year. Plasma glucose was
29.6mmol/L (534mg/dL), and urine ketone bodies were
2+. Blood gas analysis did not demonstrate acidosis (pH
7.385). Insulin therapy was started, and the requirement of
insulin was reduced to 2units/day but increased to 34 to
40 units thereafter. Postprandial C-peptide reactivity (CPR)
was 0.23nmol/L at 3 years after the onset of diabetic ketosis.
Finally,thepatientreceivedsemitotalthyroidectomyafterthe
exacerbation of thyrotoxicosis.
Patient 2 is a 34-year-old woman (at the diagnosis of
T1D). Her grandmother had type 2 diabetes. Graves’ disease
developed at age 14. After ATD therapy, she had remission
at age 19, but Graves’ disease relapsed at age 21. At age
26, Graves’ disease was exacerbated 9 months after delivery.
GADA was detected next year. Postprandial glucose was
5.3mmol/L (95mg/dL), and HbA1c was 5.0%. GADA by
RIA was 855U/ml. Three years later, Graves’ disease was
exacerbated again after her second delivery. She needed
60mg methimazole to maintain euthyroid and she took
radioisotope therapy, but an antithyroid drug was continued
as she was still thyrotoxic. One year after RI therapy, her
postprandial plasma glucose was 123mg/dL and HbA1c was
5.6%. GADA by RIA was increased to 1440U/ml. Next year
T1D developed with the manifestations of hyperglycemia
such as thirst, polydipsia, polyuria, and weight loss. On the
laboratory examinations, plasma glucose was 34.6mmol/L
(623mg/dL), HbA1c was 14.1%, urine ketone bodies were
positive, and arterial blood pH was 7.41. After initial therapy
for hyperglycemia, she took 24 units of insulin daily, and her
CPR before lunch was 0.18nmol/L.
4.Discussion
Type 1 diabetes (T1D) and Graves’ disease, both endocrine
organ-speciﬁc autoimmune diseases, frequently coexist and
in combination are classiﬁed as autoimmune polyglandular
syndrome type III [13]. There are common genetic back-
grounds for both diseases [20]s u c ha st h eC T L A - 4g e n e
[21–23] and PTPN-22 gene [24–27]. In Japanese adults, the
two diseases often develop simultaneously or Graves’ disease
proceeds to T1D [28]. Thus, Graves’ disease is a risk factor
f o rT 1 D ,a ss e e ni nt h ep r e s e n ts t u d yi nw h i c ht w oo u tJournal of Thyroid Research 3
Table 2: Baseline characteristics of the patients with positive GAD antibodies including their antibody titers.
Case Age at
entry Sex duration
(yr)
GADA
(LBA)
0
GADA
(RIA)
u/ml
<1.5
IA-2Ab
0
TRAb
(%)
<10.0
TGHA
(X)
<400
MCHA
(X)
<400
HbA1c
(%)
4.3–5.8
GTT
1 ∗ 42 M 21 >1.300 6090 0.024 63.5 400000 5.7 DM
22 1 F 0 >1.128 >256 neg 400 normal
3 ∗ 27 F 13 0.928 855 neg 21.5 400000 5.0
4 50 F 11 0.790 21.4 neg 7.2 400 100000 IGT
5 26 F 0 0.192 2.6 neg 6.7 1600 25600 normal
6 23 F 5 0.076 neg 24.2 100000
7 25 F 4 0.073 3.3 neg 29.5 400000 4.4 normal
8 42 F 2 0.062 0.5 neg 21.1 4.9
9 25 M 6 0.047 <0.4 0.083 7.0 6400 3.9
10 42 F 12 0.027 <0.4 neg 12.5 4.8
Figures at the bottom of the items are reference values.
∗Cases 1 and 3 developed T1D.
neg: negative.
Age: age at examination of GAD antibodies.
TRAb: TSH receptor antibodies, TGHA: thyroglobulin hemagglutination, MCHA: microsome hemoagglutination.
of 158 patients with Graves’ disease developed T1D during
t h ec o u r s eo f8y e a r s .
In this study, the prevalence of GADA in Graves’ patients
without previously diagnosed diabetes was high, similar to
those in previous reports [15–17]. Furthermore, the preva-
lence was high in the treated patients but the diﬀerence of
the prevalence between treated patients and treatment-na¨ ıve
patients was not statistically signiﬁcant. Among the patients
positive for GADA, T1D developed in two patients with
long-standing Graves’ disease who were not easily controlled
by antithyroid drug (ATD) therapy. One needed a 10 to
20mg methimazole for control of the disease and ﬁnally
hada thyroidectomy afterexacerbation.The otherfrequently
relapsed and ﬁnally had radioiodine therapy. Their titers of
GADA both by ligand-binding assay and radioimmunoassay
were veryhigh.Itis conceivablethatautoimmunereaction to
islet antigens is strong in the Graves’ patients with high titer
of GADA, and that those patients are susceptible to T1D.
Antibodies to islet antigens are present before the onset
of type 1 diabetes [7]. On the other hand, many individuals
positive for antibodies to islet antigens do not develop T1D.
In Finland, where the incidence of T1D is very high, it
was reported that T1D developed only in 26% of GADA-
positive young subjects from general population over 25
years [29] .I nt h es a m es t u d y ,o n l y0 . 2 6 %o fG A D A - n e g a t i v e
subjects developed T1D. Previous studies have revealed
that positivity for more than 2 kinds of islet-associated
antibodies, especially the combination of GADA and IA-2
antibodies, has predictive value [2]. Of the patients in the
present study who developed T1D, one had IA-2 antibodies
and the other did not. On the contrary, one patient who had
both antibodies in low titers did not develop T1D during
the followup period. The number of patients was small and
we could not obtain conclusive results, but the presence of
both GADA and IA-2 antibodies seems to indicate a high
risk also in Graves’ patients. Screening of GADA followed by
examination of IA-2 antibodies may allow detecting those
patients at greater risk for development of T1D, and careful
followup may provide earlier detection of the onset of T1D
in these patients.
5.Conclusions
We show preliminarily that Graves’ patients with long dura-
tion and high titers of GADA are at high risk for developing
T1D. To clarify what factors are involved in the susceptibility
to T1D in Graves’ disease, greater numbers of patients need
to be followed up intensively over a long period of time.
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